75 completed, 12 unknown, 10 terminated, 5 recruiting. 27 Not applicable, 25 Phase 2, 22 Phase 1, 19 Phase 3, 11 Phase 4.
Follow Ganciclovir: new trials by email Literature Review of Ganciclovir trials Research Report on Ganciclovir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II Valganciclovir, Ganciclovir (GCV), Placebo - Cytomegalovirus (CMV), Anterior Uveitis | Phase 2 | Not yet recruiting | University of California, San Francisco | 117 | 2026-11-01 | 2026-08-11 |
| Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients Letermovir, Placebo, Valganciclovir/Ganciclovir - CMV, Lung Transplant Recipient | Phase 4 | Recruiting | University Health Network, Toronto | 40 | 2025-12-24 | 2026-02-17 |
| Study Evaluating the Efficacy and Safety of Artesunate Artesunate, Ganciclovir (GCV) - CMV Infection | Phase 2 | Recruiting | Amivas Inc. | 90 | 2025-08-01 | 2026-08-03 |
| Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia Interleukin-2 (IL-2), Ganciclovir (GCV) - SLE (Systemic Lupus), CMV | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2025-05-20 | 2025-05-14 |
| Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis Acyclovir 400 MG, Ganciclovir (GCV) - Herpetic Keratitis | Not applicable | Completed | Al-Azhar University | 20 | 2024-10-01 | 2025-01-03 |
| Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis Ganciclovir Oral Capsule, Ganciclovir Simulant Oral Capsule, Mometasone Nasal - Rhinitis, Allergic | Not applicable | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 50 | 2024-05-24 | 2026-07-13 |
| Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection Letermovir 480 MG, Ganciclovir - CMV Infection | Phase 3 | Unknown | Hospital do Rim e Hipertensão | 100 | 2024-05-05 | 2024-04-02 |
| CMV CTLs in Neonates With CMV Infection CMV Cytotoxic T-Lymphocytes, Anti-viral Therapy - Congenital Cytomegaloviral (CMV) Disease | Phase 2 | Recruiting | New York Medical College | 23 | 2023-07-01 | 2026-03-30 |
| Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid Stimotimagene copolymerplasmid, Ganciclovir - Sarcoma, Melanoma | Phase 1 | Completed | Gene Surgery LLC | 21 | 2022-01-01 | 2024-07-01 |
| Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis IV Ganciclovir, Normal saline - Acute Respiratory Failure | Phase 3 | Terminated | Fred Hutchinson Cancer Center | 205 | 2021-06-29 | 2026-10-20 |
| Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients Ganciclovir - Cytomegalovirus Infections | Completed | New York Medical College | 100 | 2020-09-15 | 2023-10-26 | |
| Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes Valganciclovir Hydrochloride, Ganciclovir Sodium, Placebo Oral Tablet - Cytomegalovirus Anterior Uveitis | Phase 2 / Phase 3 | Terminated | University of California, San Francisco | 51 | 2020-03-15 | 2026-03-05 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: - Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension | Recruiting | Duke University | 5000 | 2020-03-05 | 2026-08-21 | |
| Treatment of Low Dose IL-2 and Ganciclovir in Cytomegalovirus Infection Low-dose IL-2 and ganciclovir - Cytomegalovirus Infections | Phase 1 / Phase 2 | Unknown | Peking University People's Hospital | 10 | 2020-02-01 | 2020-01-13 |
| Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC) Piperacillin/tazobactam, Meropenem, Daptomycin - Therapeutic Drug Monitoring, Subarachnoid Hemorrhage | Unknown | Azienda Sanitaria-Universitaria Integrata di Udine | 104 | 2019-10-01 | 2021-07-21 | |
| Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients. Valganciclovir, Ganciclovir - Transplantation Infection, Cytomegalovirus Infections | Phase 3 | Completed | Maimónides Biomedical Research Institute of Córdoba | 150 | 2019-04-05 | 2023-09-15 |
| (Val)Ganciclovir TDM in Transplant Recipients Ganciclovir, Valganciclovir - Cytomegalovirus Infections | Unknown | University Medical Center Groningen | 100 | 2018-05-25 | 2019-10-10 | |
| Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies VRx-3996 and valganciclovir - Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders | Phase 1 / Phase 2 | Completed | Viracta Therapeutics, Inc. | 64 | 2018-03-29 | 2025-03-20 |
| Femtosecond Laser-assisted Corneal Debridement for Herpes Simplex Keratitis FLDEB, Ganciclovir (GCV), Femtosecond laser - Herpes Simplex Keratitis | Not applicable | Unknown | Chunxiao Wang | 100 | 2017-07-20 | 2018-02-22 |
| Population Pharmacokinetics of Anti-infective Drugs in Children With Infectious Diseases cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs - Children; Infection | Unknown | Beijing Children's Hospital | 800 | 2017-06-21 | 2017-12-19 |
Showing 20 of 106. Sign in to see all of them.
Cytomegalovirus Infections (49) · Multiple Acyl Coenzyme A Dehydrogenase Deficiency (44) · HIV Infections (36) · Acquired Immunodeficiency Syndrome (32) · Cytomegalovirus Retinitis (27) · Retinitis (20) · AIDS-Related Opportunistic Infections (16) · Lymphoma (6) · Burkitt Lymphoma (4) · Hodgkin Disease (4) · Adenoviridae Infections (3) · Immunoblastic Lymphadenopathy (3) · Infections (3) · Leukemia (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3)
National Institute of Allergy and Infectious Diseases (NIAID) (22) · Hoffmann-La Roche (14) · Fred Hutchinson Cancer Center (4) · City of Hope Medical Center (3) · Roche Global Development (3) · HemaQuest Pharmaceuticals Inc. (2) · Johns Hopkins Bloomberg School of Public Health (2) · National Center for Research Resources (NCRR) (2) · New York Medical College (2) · Peking University People's Hospital (2) · Shire (2) · University Health Network, Toronto (2) · University of California, San Francisco (2) · AIDS Malignancy Consortium (1) · Abramson Cancer Center at Penn Medicine (1)
United States (70) · Canada (11) · China (6) · Spain (6) · Germany (5) · Italy (5) · United Kingdom (5) · Austria (4) · Australia (3) · Brazil (3) · France (3) · Switzerland (3) · Belgium (2) · Croatia (2) · Norway (2)
Michael Boeckh, MD (3) · Hardy WD (2) · John A Gonzales, MD (2) · A-Dong Shen, Master (1) · Adam Lerner, M.D. (1) · Ajit Limaye, MD (1) · Anders Hartmann, MD, Ph.D. (1) · Atul Humar, MD (1) · Borucki M (1) · Brosgart C (1) · Charles Joseph Link, MD (1) · Chi Hornik (1)
PMID 38700045, PMID 39807668, PMID 15049798, PMID 15257060, PMID 15498605, PMID 16382014, PMID 16640817, PMID 16687625, PMID 17005949, PMID 17119113, PMID 17640310, PMID 19738014, PMID 19766534, PMID 20353469, PMID 21518040, PMID 21538345, PMID 21719601, PMID 22331114, PMID 22510347, PMID 22694733, PMID 22694755, PMID 23009139, PMID 23254142, PMID 23418272, PMID 23438305, PMID 23593305, PMID 23665863, PMID 24224707, PMID 24656016, PMID 24983306, PMID 25155587, PMID 25560711, PMID 25628457, PMID 25661673, PMID 26289222, PMID 26755499, PMID 26824942, PMID 27682069, PMID 28437539, PMID 28829877, PMID 29166336, PMID 29319768, PMID 29377953, PMID 29507070, PMID 29654388, PMID 30137245, PMID 30526535, PMID 30962334, PMID 31081566, PMID 31420397
P30CA033572 (2), U10EY008057 (2), 1UG3HL147011-01A1 (1), 2015 (1), 2018 (1), M01RR000036 (1), R01AI058148 (1), R01CA090547 (1), R34AI095135 (1), U01AI027668 (1), U01AI110658 (1), U01HL102547 (1), UG1EY036344 (1)